Cascade Pharmaceuticals Inc. has synthesized thyroid hormone receptor β (THRβ) agonists reported to be useful for the treatment of MASLD/NAFLD, hypothyroidism and more.
Genzyme Corp. (dba Sanofi Genzyme) has disclosed isoxazolidine compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease and multiple sclerosis, among others.
Investigators at Ileadbms Co. Ltd. have discovered a new cyclin-dependent kinase 12 (CDK12) and CDK13 inhibitor, IL6-110, which is being developed for the treatment of cancer.
Merck & Co. Inc. has announced plans to initiate clinical development of a new investigational multi-valent human papillomavirus (HPV) vaccine designed to provide broader protection against multiple HPV types.
Alterations in mitochondrial dynamics are hallmarks of Parkinson’s disease (PD) and other neurodegenerative disorders such as Alzheimer’s disease (AD).
Asgard Therapeutics AB has announced a €30 million (US$32.7 million) series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology.
Mutations in the gene encoding calpain-3, CAPN3, are causative for autosomal recessive limb-girdle muscular dystrophy-1 (LGMDR1), a type of muscular dystrophy characterized by muscle weakening around the shoulders and hips for which there is currently no treatment.
Shanghai Henlius Biotech Inc.’s IND application for HLX-6018, a novel anti-glycoprotein-A repetitions predominant (GARP)/transforming growth factor-β1 (TGF-β1) monoclonal antibody (mAb), has received approval by China’s National Medical Products Administration (NMPA) for the treatment of idiopathic pulmonary fibrosis (IPF).
RSS
